Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Background: A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Infectious Diseases Vol. 21; no. 6; pp. 803 - 813
Autores principales:	Wu, Zhiwei, Hu, Yaling, Xu, Miao, Chen, Zhen, Yang, Wanqi, Jiang, Zhiwei, Li, Minjie, Jin, Hui, Cui, Guoliang, Chen, Panpan, Wang, Lei, Zhao, Guoqing, Ding, Yuzhu, Zhao, Yuliang, Yin, Weidong
Formato:	research Journal Article
Publicado:	Elsevier B.V. Jun2021
Acceso en línea:	Ver este registro en EBSCOhost